Urinary 8-OHdG elevations in a partial lesion rat model of parkinson's disease correlate with behavioral symptoms and nigrostriatal dopaminergic depletion

Journal of Cellular Physiology

Volumn 226, Issue 5, 2011, Pages 1390-1398

  Kikuchi, Yoichiro ^a   Yasuhara, Takao ^a   Agari, Takashi ^a   Kondo, Akihiko ^a   Kuramoto, Satoshi ^a   Kameda, Masahiro ^a   Kadota, Tomohito ^a   Baba, Tanefumi ^a   Tajiri, Naoki ^a   Wang, Feifei ^a   Tayra, Judith T ^a   Liang, Hanbai ^a   Miyoshi, Yasuyuki ^a   Borlongan, Cesario V ^b   Date, Isao ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

8 HYDROXYDEOXYGUANOSINE; OXIDOPAMINE; TYROSINE 3 MONOOXYGENASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BEHAVIOR DISORDER; CONTROLLED STUDY; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC NERVE CELL; DOPAMINERGIC SYSTEM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; NERVE CELL DEGENERATION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATIVE STRESS; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; STAINING; SURVIVAL RATE; URINALYSIS;

ANIMALS; BASAL GANGLIA; BEHAVIOR, ANIMAL; BIOLOGICAL MARKERS; BRAIN; DEOXYGUANOSINE; DISEASE MODELS, ANIMAL; DISEASE PROGRESSION; DOPAMINE; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOHISTOCHEMISTRY; INJECTIONS; MOTOR ACTIVITY; NERVE DEGENERATION; OXIDATIVE STRESS; OXIDOPAMINE; PARKINSONIAN DISORDERS; RATS; RATS, SPRAGUE-DAWLEY; SEVERITY OF ILLNESS INDEX; SUBSTANTIA NIGRA; TIME FACTORS; TYROSINE 3-MONOOXYGENASE;

ANIMALIA; RATTUS;

EID: 79951805276     PISSN: 00219541     EISSN: 10974652     Source Type: Journal    
DOI: 10.1002/jcp.22467     Document Type: Article

References (52)

1. Alam ZI, Jenner A, Daniel SE, Lees AJ, Cairns N, Marsden CD, Jenner P, Halliwell B. 1997. Oxidative DNA damage in the parkinsonian brain: an apparent selective increase in 8-hydroxyguanine levels in substantia nigra. J Neurochem 69: 1196-1203.
2. Berg D. 2008. Biomarkers for the early detection of Parkinson's and Alzheimer's disease. Neurodegener Dis 5: 133-136.
3. Betarbet R, Sherer TB, Greenamyre JT. 2002. Animal models of Parkinson's disease. Bioessays 24: 308-318.
4. Blandini F, Armentero MT, Martignoni E. 2008. The 6-hydroxydopamine model: news from the past. Parkinsonism Relat Disord 14: S124-S129.
5. Bloomer RJ, Fisher-Wellman KH. 2008. Blood oxidative stress biomarkers: influence of sex, exercise training status, and dietary intake. Gend Med 3: 218-228.
6. Blum D, Torch S, Lambeng N, Nissou M, Benabid AL, Sadoul R, Verna JM. 2001. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65: 135-172.
7. Bogdanov M, Brown RH, Matson W, Smart R, Hayden D, O'Donnell H, Flint Beal M, Cudkowicz M., 2002. Increased oxidative damage to DNA in ALS patients. Free Radic Biol Med 29: 652-658.
8. Bogdanov M, Matson WR, Wang L, Matson T, Saunders-Pullman R, Bressman SS, Flint Beal M., 2008. Metabolomic profiling to develop blood biomarkers for Parkinson's disease. Brain 131: 389-396.
9. Borlongan CV, Sanberg PR. 1995. Elevated body swing test: a new behavioral parameter for rats with 6-hydroxydopamine-induced hemiparkinsonism. J Neurosci 7: 5372-5378.
10. Bové J, Prou D, Perier C, Przedborski S. 2005. Toxin-induced models of Parkinson's disease. Neuro Rx 2: 484-494.
11. Braak H, Del Tredici K. 2008. Invited Article: nervous system pathology in sporadic Parkinson disease. Neurology 70: 1916-1925.
12. Chen CM, Liu JL, Wu YR, Chen YC, Cheng HS, Cheng ML, Chiu DT. 2009. Increased oxidative damage in peripheral blood correlates with severity of Parkinson's disease. Neurobiol Dis 3: 429-435.
13. Dexter D, Carter C, Agid F, Agid Y, Lees AJ, Jenner P, Marsden CD. 1986. Lipid peroxidation as cause of nigral cell death in Parkinson's disease. Lancet 2: 639-640.
14. Faull RL, Laverty R. 1969. Changes in dopamine levels in the corpus striatum following lesions in the substantia nigra. Exp Neurol 23: 332-340.
15. Fearnley J, Lees AJ. 1991. Pathology of Parkinson's disease. In: Calne DB, editor. Neurodegenerative diseases. Philadelphia: Saunders. pp 545-554.
16. Ferrante RJ, Browne SE, Shinobu LA, Bowling AC, Baik MJ, MacGarvey U, Kowall NW, Brown RH Jr, Beal MF. 1997. Evidence of increased oxidative damage in both sporadic and familial amyotrophic lateral sclerosis. J Neurochem 69: 2064-2074.
17. Fitzmaurice PS, Ang L, Guttman M, Rajput AH, Furukawa Y, Kish SJ. 2003. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease. Mov Disord 18: 969-976.
18. Forno LS. 1969. Concentric hyalin intraneuronal inclusions of Lewy type in the brain of elderly persons (50 incidental cases): relationship to Parkinsonism. J Am Geriatr Soc 17: 557-575.
19. Fornstedt B, Rosengren E, Carlsson A. 1986. Occurrence and distribution of 5-S-cysteinyl derivatives of dopamine, dopa and dopac in the brains of eight mammalian species. Neuropharmacology 25: 451-454.
20. Goto M, Ueda K, Hashimoto T, Fujiwara S, Matsuyama K, Kometani T, Kanazawa K. 2008. A formation mechanism for 8-hydroxy-2'-deoxyguanosine mediated by peroxidized 2'-deoxythymidine. Free Radic Biol Med 45: 1318-1325.
21. Harley A, Cooper JM, Schapira AH. 1993. Iron induced oxidative stress and mitochondrial dysfunction: relevance to Parkinson's disease. Brain Res 627: 349-353.
22. Hersch SM, Gevorkian S, Marder K, Moskowitz C, Feigin A, Cox M, Como P, Zimmerman C, Lin M, Zhang L, Ulug AM, Beal MF, Matson W, Bogdanov M, Ebbel E, Zaleta A, Kaneko Y, Jenkins B, Hevelone N, Zhang H, Yu H, Schoenfeld D, Ferrante R, Rosas HD. 2006. Creatine in Huntington disease is safe, tolerable, bioavailable in brain and reduces serum 8OH2'dG. Neurology 66: 250-252.
23. Hilker R, Schweitzer K, Coburger S, Ghaemi M, Weisenbach S, Jacobs AH, Rudolf J, Herholz K, Heiss WD. 2005. Nonlinear progression of Parkinson disease as determined by serial positron emission tomographic imaging of striatal fluorodopa F 18 activity. Arch Neurol 62: 378-382.
24. Hughes AJ, Ben-Shlomo Y, Daniel SE, Lees AJ. 2001. What features improve the accuracy of clinical diagnosis in Parkinson's disease: a clinicopathologic study. Neurology 57: S34-S38.
25. Jenner P, Dexter DT, Sian J, Schapira AH, Marsden CD. 1992. Oxidative stress as a cause of nigral cell death in Parkinson's disease and incidental Lewy body disease. The Royal Kings and Queens Parkinson's Disease Research Group. Ann Neurol 32: S82-S87.
26. Kameda M, Shingo T, Takahashi K, Muraoka K, Kurozumi K, Yasuhara T, Maruo T, Tsuboi T, Uozumi T, Matsui T, Miyoshi Y, Hamada H, Date I. 2007. Adult neural stem and progenitor cells modified to secrete GDNF can protect, migrate and integrate after intracerebral transplantation in rats with transient forebrain ischemia. Eur J Neurosci 6: 1462-1478.
27. Kikuchi A, Takeda A, Onodera H, Kimpara T, Hisanaga K, Sato N, Nunomura A, Castellani RJ, Perry G, Smith MA, Itoyama Y. 2002. Systemic increase of oxidative nucleic acid damage in Parkinson's disease and multiple system atrophy. Neurobiol Dis 9: 244-248.
28. Koller WC. 1992. When does Parkinson's disease begin? Neurology 42: 27-31.
29. Lovell MA, Gabbita SP, Markesbery WR. 1999. Increased DNA oxidation and decreased levels of repair products in Alzheimer's disease ventricular CSF. J Neurochem 72: 771-776.
30. Mecocci P, MacGarvey U, Beal MF. 1994. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36: 747-751.
31. Miller RL, James-Kracke M, Sun GY, Sun AY. 2009. Oxidative and inflammatory pathways in Parkinson's disease. Neurochem Res 34: 55-65.
32. Nakabeppu Y, Tsuchimoto D, Yamaguchi H, Sakumi K. 2007. Oxidative damage in nucleic acids and Parkinson's disease. J Neurosci Res 85: 919-934.
33. Paxinos G, Watson G. 1998. The rat brain in stereotaxic coordinates, 4th edition. San Diego: Academic Press.
34. Pilger A, Germadnik D, Riedel K, Meger-Kossien I, Scherer G, Rüdiger HW. 2001. Longitudinal study of urinary 8-hydroxy-2'-deoxyguanosine excretion in healthy adults. Free Radic Res 3: 273-280.
35. Przedborski S, Levivier M, Jiang H, Ferreira M, Jackson-Lewis V, Donaldson D, Togasaki DM. 1995. Dose-dependent lesions of the dopaminergic nigrostriatal pathway induced by intrastriatal injection of 6-hydroxydopamine. Neuroscience 67: 631-647.
36. Roof RL, Schielke GP, Ren X, Hall ED. 2001. A comparison of longterm functional outcome after 2 middle cerebral artery occlusion models in rats. Stroke 32: 2648-2657.
37. Sakano N, Wang DH, Takahashi N, Wang B, Sauriasari R, Kanbara S, Sato Y, Takigawa T, Takaki J, Ogino K. 2009. Oxidative stress biomarkers and lifestyles in Japanese healthy people. J Clin Biochem Nutr 2: 185-195.
38. Sato S, Mizuno Y, Hattori N. 2005. Urinary 8-hydroxydeoxyguanosine levels as a biomarker for progression of Parkinson disease. Neurology 64: 1081-1083.
39. Schallert T, Fleming SM, Leasure JL, Tillerson JL, Bland ST. 2002. CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology 39: 777-787.
40. Schober A. 2004. Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res 318: 215-224.
41. Schulz JB, Dermer T, Schols L, Mende H, Hardt C, Vorgerd M, Burk K, Matson W, Dichgans J, Beal MF, Bogdanov MB. 2000. Oxidative stress in patients with Friedreich ataxia. Neurology 55: 1719-1721.
42. Shamoto-Nagai M, Maruyama W, Hashizume Y, Yoshida M, Osawa T, Riederer P, Naoi M. 2007. In parkinsonian substantia nigra, alpha-synuclein is modified by acrolein, a lipid-peroxidation product, and accumulates in the dopamine neurons with inhibition of proteasome activity. J Neural Transm 114: 1559-1567.
43. Sofic E, Sapcanin A, Tahirovic I, Gavrankapetanovic I, Jellinger K, Reynolds GP, Tatschner T, Riederer P. 2006. Antioxidant capacity in postmortem brain tissues of Parkinson's and Alzheimer's diseases. J Neural Transm 71: 3943.
44. Spiegel J, Storch A, Jost WH. 2006. Early diagnosis of Parkinson's disease. J Neurol 253: 2-7.
45. Takahashi K, Yasuhara T, Shingo T, Muraoka K, Kameda M, Takeuchi A, Yano A, Kurozumi K, Agari T, Miyoshi Y, Kinugasa K, Date I. 2008. Embryonic neural stem cells transplanted in middle cerebral artery occlusion model of rats demonstrated potent therapeutic effects, compared to adult neural stem cells. Brain Res 1234: 172-182.
46. Thakar JH, Hassan MN. 1988. Effects of 6-hydroxydopamine on oxidative phosphorylation of mitochondria from rat striatum, cortex, and liver. Can J Physiol Pharmacol 66: 376-379.
47. Valavanidis A, Vlachogianni T, Fiotakis C. 2009. 8-hydroxy-2' -deoxyguanosine (8-OHdG): a critical biomarker of oxidative stress and carcinogenesis. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev 2: 120-139.
48. Vali S, Mythri RB, Jagatha B, Padiadpu J, Ramanujan KS, Andersen JK, Gorin F, Bharath MM. 2007. Integrating glutathione metabolism and mitochondrial dysfunction with implications for Parkinson's disease: a dynamic model. Neuroscience 149: 917-930.
49. Yasuhara T, Hara K, Sethi KD, Morgan JC, Borlongan CV. 2007. Increased 8-OHdG levels in the urine, serum, and substantia nigra of hemiparkinsonian rats. Brain Res 1133: 49-52.
50. Yuan H, Sarre S, Ebinger G, Michotte Y. 2005. Histological, behavioural and neurochemical evaluation of medial forebrain bundle and striatal 6-OHDA lesions as rat models of Parkinson's disease. J Neurosci Methods 144: 35-45.
51. Yuan WJ, Yasuhara T, Shingo T, Muraoka K, Agari T, Kameda M, Uozumi T, Tajiri N, Morimoto T, Jing M, Baba T, Wang F, Leung H, Matsui T, Miyoshi Y, Date I. 2008. Neuroprotective effects of edaravone-administration on 6-OHDA-treated dopaminergic neurons. BMC Neurosci 9: 75.
52. Zhang SM, Hernán MA, Chen H, Spiegelman D, Willett WC, Ascherio A. 2002. Intakes of vitamins E and C, carotenoids, vitamin supplements, and PD risk. Neurology 59: 1161-1169.